V 3XAlternative Names: Oral therapeutic vaccine V3-X; V3-X
Latest Information Update: 15 Feb 2017
At a glance
- Originator Immunitor
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cholangiocarcinoma
Most Recent Events
- 01 Feb 2017 Phase-I/II clinical trials in Cholangiocarcinoma in Mongolia (PO) (NCT03042182)